Reimagining Care for Neurodegenerative Diseases
We harness the power of software to build evidence-based, precision digital therapeutics for neurodegenerative diseases.
By combining best-in-class cognitive rehabilitation strategies and machine learning approaches, our digital therapeutic and monitoring tools empower patients, families and clinicians by helping to preserve cognition and independence.
Reimagining Care for Neurodegenerative Diseases
We harness the power of software to build evidence-based, precision digital therapeutics for neurodegenerative diseases.
By combining best-in-class cognitive rehabilitation strategies and machine learning approaches, our digital therapeutic and monitoring tools empower patients, families and clinicians by helping to preserve cognition and independence.
Alzheimer's and MCI
- a huge clinical unmet need
Over 50 million people worldwide suffer from Alzheimer’s disease (AD) and an equal number show signs of mild cognitive impairment (MCI), a potential precursor of the disease. Additionally, 150 million people may have pre-clinical dementia due to genetic risks and silent neuropathological changes. Currently approved symptomatic therapies offer only modest cognitive benefits and drop-out rates due to perceived lack of efficacy remain high. Several investigational drugs are in the pipeline but their success remains uncertain. Growing evidence supports the importance of complementary non-pharmacologic therapies such as cognitive rehabilitation, multi-domain lifestyle intervention, and patient education/support.
Developing digital therapeutics for AD/MCI
At Neuroglee Therapeutics, we are developing an investigational prescription digital therapeutic (DTx) that can be used independently or in conjunction with a pharmacotherapy for treating neurodegenerative diseases. Unlike wellness apps, digital therapeutics are designed to be used under the supervision of a clinician and undergo regulatory review/clearance for treating a specific disease.
Our initial software product, NG-001, is intended for the symptomatic treatment of Alzheimer's disease/MCI. It aims to provide a more personalized and engaging experience than existing non-pharmacological solutions. Through NG-001, our software captures digital biomarkers and learns from user behavior to provide a more personalized experience, resulting in best-fit therapy that is tailored to meet patient needs.
Baseline Assessment
Using advanced artificial intelligence, NG-001 continuously tracks digital biomarkers and performs a baseline assessment.
Cognitive Intervention
Based on assessment data, NG-001 personalizes each patient’s therapy by automatically adjusting the therapeutic mobile-based intervention for best results.
Continuous Monitoring
NG-001 constantly monitors cognitive health, physiology and lifestyle biomarkers using advanced biosensors and intuitive digital tools.
Transforming the treatment ecosystem
NG-001 features digital tools for patients, caregivers and clinicians for more streamlined, efficient collaboration on neurodegenerative disease management.
Besides improving patient health outcomes and quality of life, efficient digital therapeutics also reduces the caregiving burden, accelerates the development of effective drugs in the pipeline.
Patients
Patients engage with the NG-001 app on a daily basis to access therapies and treatment schedules according to their conditions.
Caregivers
Caregivers can interact with and guide patients through their therapies on their own dashboard. They can also check patient progress and responses.
Clinicians
Clinicians can oversee patient medication adherence and therapeutic responses. This allows them to accurately asses drug and treatment efficacy.
NG-001 supports the ecosystem of care
around neurodegenerative diseases
NG-001 supports the ecosystem of care around neurodegenerative diseases
Patients
Can improve their recall and cognitive abilities
Can better adhere to medication and treatment schedules
Can receive external support
Can reduce uncertainty and manage emotions
Clinicians
Can track patient medication adherence and drug efficacy
Can adjust treatment and dosage
Can remotely monitor patient progress
Caregivers
Can support patients through their therapies
Can remotely monitor patient progress
Can enjoy a better quality of life through simplified and more effective caregiving
The minds behind the science
A world-class founding team with vast experience in cognitive neuroscience, dementia clinical trials, wearables and artificial intelligence.
Aniket Singh Rajput
Founder & CEO
Specializing in Robotics and Cognitive Neuroscience, Aniket is the driving force behind Neuroglee's mission to treat the untreatable.
Dr Murali Doraiswamy
Co-Founding Scientific Advisor
A globally respected expert on Alzheimer’s disease and precision medicine, Dr Murali is a professor at the Duke University School of Medicine.
Dr Michael D. Patterson
Principal Cognitive Scientist
Dr Michael has published highly-cited papers on cognitive enhancement and measurement. His expertise contributed to the development of Neuroglee's MOA.
Bikram Aditya Gangwar
AI Solution Architect
With extensive experience in data analysis and machine learning, Bikram's insight has been crucial in Neuroglee's software development.
Piyush Pandya
Sr UI/UX Designer
Piyush leverages over eight years of design experience to create simplified, intuitive interfaces, making Neuroglee software more accessible.
Dr Priyanka Ebnezar
Digital Content Writer
Formerly an editor on India’s largest academic network of doctors, Dr Priyanka creates content that effectively unpacks the science behind Neuroglee.Request for a FREE Quote
Lorem Ipsum is simply dummy text of the printing and typesetting has been the industry's standard dummy text.
In the media
Neuroglee Therapeutics, a healthtech startup building evidence-based, prescription digital therapeutics for neurodegenerative diseases, announced that it has raised US$2.3 million in pre-seed funding.
e27
Neuroglee discovers, develops, and commercializes software as medical treatment for patients with neurodegenerative diseases.
Tech in Asia
Neuroglee Therapeutics raises $2.3M in pre-seed funding to advance digital therapeutics for neurodegenerative diseases.
TechCrunch
HEALTHTECH startup Neuroglee has secured US$2.3 million in pre-seed funding to advance its product pipeline for the treatment and management of patients at the early stage of Alzheimer's disease.
business times